A single‐arm clinical study has suggested that individuals with advanced NSCLC and EGFR mutations who receive thoracic radiotherapy combined with EGFR‐TKIs can control their primary lung tumors for a prolonged duration.37 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.